Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 10/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 3/20 | 0.32 |
| ▸ | FPR1 | P21462 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5180557 | 0.90 | ELANE (0.38) | ELANEROCK2SYK | |
| SCHEMBL5178983 | 0.88 | ELANE (0.37) | ELANEROCK2SYK | |
| SCHEMBL5811828 | 0.88 | ROCK2 (0.32) | ROCK2SYKFPR1FPR2 | |
| SCHEMBL5166655 | 0.85 | ROCK2 (0.41) | ELANEROCK2 | |
| SCHEMBL5165708 | 0.84 | FPR2 (0.40) | ELANEFPR1FPR2 | |
| SCHEMBL5166513 | 0.81 | ELANE (0.41) | ELANEROCK2 | |
| SCHEMBL5163829 | 0.81 | FPR2 (0.41) | ELANEROCK2FPR1FPR2 | |
| SCHEMBL5762169 | 0.80 | MCHR1 (0.38) | ELANEROCK2 | |
| SCHEMBL5165446 | 0.80 | ELANE (0.39) | ELANEROCK2 | |
| SCHEMBL5163793 | 0.80 | ROCK2 (0.42) | ELANEROCK2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768975-A2 | PYRIDYL PIPERAZINES FOR THE TREATMENT OF CNS DISORDERS | Pfizer Products Inc. (US) | 2007-04-04 | — | — | EP | claimed |
| US-20060025421-A1 | Pyridyl piperazines for the treatment of CNS disorders | PFIZER INC | 2006-02-02 | — | — | US | claimed |
| WO-2006000912-A2 | PYRIDYL PIPERAZINES FOR THE TREATMENT OF CNS DISORDERS | PFIZER PRODUCTS INC. (US) | 2006-01-05 | — | — | WO | claimed |
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| US-20060025421-A1 | Pyridyl piperazines for the treatment of CNS disorders | PFIZER INC | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025421-A1 | Pyridyl piperazines for the treatment of CNS disorders | TPH2, HTR1A, TPH1 | ELANE 4841/4885ROCK2 769/4885TLR7 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.